Adult hemolytic uremic syndrome
Article Sidebar
Main Article Content
Abstract
Hemolytic uremic syndrome (HUS), described in 1955, is characterized by the triad of non-immune mediated hemolytic anemia, thrombocytopenia, and acute kidney injury. Shiga toxin, produced most frequently by E coli O157:H, is involved in its pathogenesis.
Hus can manifest at any age, although it is rare in adults and develops sporadically or in outbreaks. HUS presents with a picture of abdominal pain, diarrhea, fever and vomiting. It can affect the central nervous system, lungs, pancreas, and heart.
In adults, the syndrome evolves after an incubation period of 1 week after diarrhea, with high morbidity and mortality, unlike pediatric cases.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Cowden J M. Brote de Escherichia coli O157 en Escocia, noviembre-diciembre 1996. Euro Surveill. 1997;2(1):pii=134. https://doi.org/10.2807/esm.02.01.00134-es
Dundas S, Todd WT, Stewart AI, et al.. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis. 2001;33(7):923-931. https://doi.org/10.1086/322598.
Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365(9464):1073-1086. https://doi.org/10.1016/S0140-6736(05)71144-2.
Travert B, Dossier A, Jamme M, et al. Shiga toxin-associated hemolytic uremic syndrome in adults, France, 2009-2017. Emerg Infect Dis. 2021;27(7):1876-1885. https://doi.org/10.3201/eid2707.204638.
Joseph A, Cointe A, Mariani Kurkdjian P, et al. Shiga toxin-associated hemolytic uremic syndrome: a narrative review. Toxins. 2020;12(2):67. https://doi.org/10.3390/toxins12020067.
Organización Mundial de la Salud. 1996 Escherichia coli enterohemorrágica en Japón. Ginebra: WHO; actualizado 2015 [consulta 2022 oct 10]. Disponible en: http://www.who.int/csr/don/1996_08_28/e.
Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157: H7 infections. N Engl J Med. 2000;342(26):1930-1936. https://doi.org/10.1056/NEJM200006293422601.
Ikeda K, Ida O, Kimoto K, et al. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol. 1999;52(6):357-362.
Takeda T. Strategy to prevent the progression of enterohemorrhagic escherichia coli O157 Infection to hemolytic uremic syndrome. Jpn J Med Sci Biol.1998;51(S1):S124-S128. ttps://doi.org/10.7883/yoken1952.51.Supplement1_S124.
Kakoullis L, Papachristodoulou E, Chra P, et al. Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview. J Infect. 2019;79(2):75-94. https://doi.org/10.1016/j.jinf.2019.05.018.
Davis TK, McKee R, Schnadower D, et al. Treatment of shiga toxin-producing escherichia coli infections. Infect Dis Clin North Am. 2013;27(3):577-597. https://doi.org/10.1016/j.idc.2013.05.010.
Cavero T, Praga Terente M. Síndrome hemolítico urémico. En: En: Lorenzo V, López Gómez JM, eds. Nefrología al Día [Internet]. Madrid: Sociedad Española de Nefrología; actualización 2021 dic 12 [consulta 2023 feb 22]. Disponible en: https://www.nefrologiaaldia.org/es-articulo-sindrome-hemolitico-uremico-216.
Leotta GA, Chinen I, Epszteyn S, et al. Validación de una técnica de PCR múltiple para la detección de Escherichia coli productor de toxina Shiga. Rev Argent Microbiol. 2005;37(1):3-10.